Menu Search
Equities

Eupraxia Pharmaceuticals Inc

EPRX:TOR

Eupraxia Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)3.85
  • Today's Change-0.05 / -1.28%
  • Shares traded3.30k
  • 1 Year change-46.60%
  • Beta1.2385
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The 2 analysts offering 12 month price targets for Eupraxia Pharmaceuticals Inc have a median target of 12.38, with a high estimate of 16.50 and a low estimate of 8.25. The median estimate represents a 221.56% increase from the last price of 3.85.
High328.6%16.50
Med221.6%12.38
Low114.3%8.25

Earnings history & estimates in CAD

On Aug 07, 2024, Eupraxia Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.233 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 35.28%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+5.44%
Eupraxia Pharmaceuticals Inc reported annual 2023 losses of -1.17 per share on Apr 01, 2024.
Average growth rate+19.47%
More ▼

Revenue history & estimates in CAD

Eupraxia Pharmaceuticals Inc did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Eupraxia Pharmaceuticals Inc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.